FDA Approves Expanded Indication for Jaypirca

TUESDAY, Dec. 9, 2025-- The U.S. Food and Drug Administration has approved an expanded indication for Jaypirca (pirtobrutinib), the first and only noncovalent Bruton tyrosine kinase (BTK) inhibitor for adults with relapsed or refractory chronic...